New drug RAB001 takes first step in human safety trials
NCT ID NCT07545018
First seen Apr 22, 2026 · Last updated May 08, 2026 · Updated 6 times
Summary
This early-stage study tested the safety and tolerability of a new drug called RAB001 in 16 healthy adults. Researchers gave single and multiple injections at two dose levels to see how the body handles the drug and if it causes any side effects. This is a first step toward possibly treating osteonecrosis of the femoral head, a condition where bone tissue dies due to poor blood supply.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEONECROSIS OF THE FEMORAL HEAD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hebei University Affiliated Hospital
Baoding, Hebei, 071000, China
Conditions
Explore the condition pages connected to this study.